Novartis asks FDA to expand Kymriah’s use against blood cancer – Nasdaq
Nasdaq |
Novartis asks FDA to expand Kymriah's use against blood cancer
Nasdaq With CAR–T therapies, patients' immune cells are taken from their bodies, genetically re-engineered to fight their cancer and then reinfused. Novartis has set the price for Kymriah at $475,000 for young patients with ALL, but the Basel-based company … Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking … |
